Rollins Financial’s Novavax NVAX Stock Holding History

Rollins Financial’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,640	Closed	-$341K	–	108
2022 Q2	$341K	Buy	+6,640	New	+$344K	0.12%	85

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Rollins Financial's NVAX Position: Q3 2022 in Review

Rollins Financial sold out of Novavax (NVAX) in Q3 2022, closing a stake of 6,640 shares — an estimated $341K sold.

Rollins Financial first reported a position in NVAX in Q2 2022 and held it in 1 quarter. The position peaked at $341K in Q2 2022. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

Rollins Financial reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
Rollins Financial sold 6,640 Novavax shares in Q3 2022, an estimated $341K.
Rollins Financial first reported a position in Novavax in Q2 2022 and held it in 1 quarter.
Rollins Financial's Novavax position peaked at $341K in Q2 2022.
253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Rollins Financial's 13F filing for Q3 2022, filed 9 Nov 2022.